ENTA Enanta Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ENTA

Price (delayed)

$11.72

Market cap

$340.8M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.6

Enterprise value

$362.41M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 49
Relative Valuation: Rel. Valuation: 13
Relative Profitability: Rel. Profitability: 41

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections ...

Highlights
The EPS has grown by 43% year-on-year and by 19% since the previous quarter
ENTA's net income is up by 36% year-on-year and by 13% since the previous quarter
The equity has increased by 25% YoY but it has decreased by 8% from the previous quarter
Enanta Pharmaceuticals's quick ratio has decreased by 15% YoY and by 15% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.enanta.com
Peers: VRTX JNJ ABBV MRK

Key stats

What are the main financial stats of ENTA

ENTA stock price

How has the Enanta Pharmaceuticals stock price performed over time
Intraday
4.27%
1 week
-11.41%
1 month
-19.39%
1 year
64.84%
YTD
-25.68%
QTD
-7.21%

Financial performance

How have Enanta Pharmaceuticals's revenue and profit performed over time
Revenue
$69.21M
Gross profit
$69.21M
Operating income
-$60.38M
Net income
-$61.98M
Gross margin
100%
Net margin
-89.6%
The operating margin has grown by 45% YoY and by 20% from the previous quarter
The company's operating income rose by 41% YoY and by 17% QoQ
The net margin has grown by 40% YoY and by 16% from the previous quarter
ENTA's net income is up by 36% year-on-year and by 13% since the previous quarter

Price vs fundamentals

How does ENTA's price correlate with its fundamentals

Growth

What is Enanta Pharmaceuticals's growth rate over time

Valuation

What is Enanta Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.92
P/S
4.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.24
The EPS has grown by 43% year-on-year and by 19% since the previous quarter
The equity has increased by 25% YoY but it has decreased by 8% from the previous quarter
ENTA's P/B is 13% below its last 4 quarters average of 3.2 but 12% above its 5-year quarterly average of 2.5
The price to sales (P/S) is 34% lower than the 5-year quarterly average of 7.2 but 2.6% higher than the last 4 quarters average of 4.6
Enanta Pharmaceuticals's revenue has increased by 7% YoY and by 3.3% from the previous quarter

Efficiency

How efficient is Enanta Pharmaceuticals business performance
The return on sales has grown by 47% year-on-year and by 22% since the previous quarter
ENTA's return on invested capital is up by 37% year-on-year and by 20% since the previous quarter
Enanta Pharmaceuticals's ROA has increased by 24% YoY and by 13% from the previous quarter
Enanta Pharmaceuticals's return on equity has increased by 20% YoY and by 19% QoQ

Dividends

What is ENTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENTA.

Financial health

How did Enanta Pharmaceuticals financials performed over time
The company's total assets is 59% higher than its total liabilities
Enanta Pharmaceuticals's current ratio has decreased by 27% YoY and by 14% from the previous quarter
Enanta Pharmaceuticals's quick ratio has decreased by 15% YoY and by 15% QoQ
The debt is 52% less than the equity
The equity has increased by 25% YoY but it has decreased by 8% from the previous quarter
The company's debt to equity fell by 24% YoY but it rose by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.